slides · global inventory
Table
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 60,568
Current window 26,521-26,550
Pages 2,019
Rows per page 30
Component
26,521-26,550 of 60,568
17
The slide uses a narrative of 'fraud' to frame the company's management and reporting practices.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Monster1 hit
26
The slide uses a combination of narrative argument and a supporting table of pharmacologic approaches to justify the 'difficult' commercial landscape.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The MonsterLoop · Aha Moment1 hit
46
The slide uses legal filings and OIG reports to establish a pattern of billing abuse in the sleep sector.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Struggle1 hit
61
The slide uses a combination of narrative text and a supporting data table to argue that certain structural features are predictive of drug safety risks.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Victory1 hit
71
The slide uses a combination of chemical structure diagrams, a tabular summary of clinical trial failures, and a pie chart showing the distribution of indications for failed trials.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
72
The slide highlights BF2.649 (pitolisant) with a red box to emphasize its drug-likeness profile compared to other failed candidates.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
107
The slide uses an FDA review document to highlight a safety risk (QTc prolongation) that the company allegedly downplays.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
109
The slide uses a table to contrast initial high-dose trials with subsequent lower-dose trials to imply company knowledge of toxicity.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
114
The slide uses a critical tone to highlight potential data manipulation or poor reporting practices in a clinical trial publication.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
118
The slide uses a 'black box' argument to challenge the validity of the sponsor's pharmacokinetic model.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
123
The slide uses a red box to highlight a specific data point (40mg dose) in a table to support the argument of inconsistent reporting.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
125
The slide uses a specific data table to support a broader narrative of corporate non-transparency regarding PK data.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
126
The slide uses a table to expose data inconsistencies and safety risks, framing the variability as a 'red flag' regarding the drug's safety profile.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
128
The slide uses a direct quote from an FDA clinical review to contradict the company's safety claims, supported by a table of clinical data.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
133
The slide uses a red box to highlight the specific column in the table containing the erroneous data.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
139
The slide uses a direct excerpt from a package insert to support the argument that dose reduction is required due to drug interactions.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
143
The slide uses a ClinicalTrials.gov entry as evidence of a 'buried' or incomplete study.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
144
The slide uses a Wikipedia table to demonstrate the complexity of CYP2D6 phenotypes to undermine the validity of the FDA's small-sample study.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
148
The slide uses a combination of narrative argument and a supporting data table to challenge the safety profile of the drug.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
155
The slide uses a narrative summary followed by a supporting table (Table 4) to challenge the safety reporting of the drug.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
166
The slide uses a scientific table to challenge the 'no appreciable binding' claim found in a drug's package insert, citing reproducibility concerns regarding the source of that claim.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
167
The slide uses a medical reference to re-frame clinical trial data that was previously dismissed as unrelated.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
10
The slide uses guilt-by-association to undermine the credibility of IonQ's backers and advisors.IonQ Inc. (IONQ) · Scorpion Capital
Activist deck Short seller 1 hit
115
The slide highlights the failure of the computer to consistently return the correct answer (2).IonQ Inc. (IONQ) · Scorpion Capital
Activist deck Short seller Loop · Iceberg1 hit
118
The slide uses a red box to highlight the row corresponding to the correct answer (5).IonQ Inc. (IONQ) · Scorpion Capital
Activist deck Short seller Loop · Iceberg1 hit
143
The slide uses a snippet from a 10Q filing to contrast narrative with financial reality.IonQ Inc. (IONQ) · Scorpion Capital
Activist deck Short seller Beat · The Conclusion that IonQ's Claims are Exaggerated1 hit
147
The slide uses a 'round-tripping' argument, contrasting revenue received from related parties against expenses paid to them.IonQ Inc. (IONQ) · Scorpion Capital
Activist deck Short seller Beat · The Conclusion that IonQ's Claims are Exaggerated1 hit
148
The slide uses a table to derive Q4 figures from annual and Q3 year-to-date data, highlighting a spike in related-party revenue dependency.IonQ Inc. (IONQ) · Scorpion Capital
Activist deck Short seller Beat · The Conclusion that IonQ's Claims are Exaggerated1 hit
151
The slide uses a narrative structure to expose a contradiction between public press releases and subsequent 10Q footnote disclosures.IonQ Inc. (IONQ) · Scorpion Capital
Activist deck Short seller 1 hit
154
The slide uses red boxes to highlight specific line items in a financial table to draw attention to the alleged accounting irregularity.IonQ Inc. (IONQ) · Scorpion Capital
Activist deck Short seller 1 hit